{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:02:49Z","timestamp":1791198169011,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.beha.2016.10.014","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T02:47:39Z","timestamp":1477018059000},"page":"308-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Discontinuation of TKI therapy and \u2018functional\u2019 cure for CML"],"prefix":"10.1016","volume":"29","author":[{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.10.014_bib1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2016.10.014_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.014_bib5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.014_bib6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib7","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib8","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib13","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beha.2016.10.014_bib14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.014_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2016.10.014_bib16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2016.10.014_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2016.10.014_bib18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.014_bib19","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib20","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2016.10.014_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","article-title":"Long term results after allogeneic transplantation for chronic myelogenous leukemia in chronic phase: a report from the chronic leukemia working party of the European group for blood and marrow transplantation","volume":"20","author":"van Rhee","year":"1997","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.014_bib22","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V98.6.1701","article-title":"The significance of bcr-abl molecular detection in chronic myeloid leukemia patients \u201clate,\u201d 18 months or more after transplantation","volume":"98","author":"Radich","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib25","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood.V92.11.4059","article-title":"Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha","volume":"92","author":"Mahon","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa","volume":"20","author":"Mahon","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib27","first-page":"2299","article-title":"Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: experience of long follow up after treatment discontinuation [abstract]","volume":"116","author":"Mahon","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.beha.2016.10.014_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2016.10.014_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V124.21.811.811","volume":"124","author":"Rea","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps7124","article-title":"Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath","volume":"32","author":"Mahon","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7001","article-title":"Treatment-free remission in patients with CML-CP treated with frontline nilotinib: results from the ENESTfreedom study","volume":"34","author":"Hochhaus","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.beha.2016.10.014_bib33","article-title":"Treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with second-line nilotinib: first results from the ENESTop study","volume":"34","author":"Hughes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.014_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V124.21.151.151","article-title":"Interim analysis of a Pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study","volume":"124","author":"Mahon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.014_bib35","article-title":"Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial","volume":"101","author":"Richter","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2016.10.014_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2016.10.014_bib37","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T20:51:37Z","timestamp":1601153497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1521692616300676"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.014","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of TKI therapy and \u2018functional\u2019 cure for CML","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}